• Thurs news: Lilly’s weight-loss drug prevents diabetes. Merck pays $588M for bispecific. Amgen speaks out about bone density issues with obesity drug. PTC gets gene therapy approval. JNJ’s 340B legal fight. See more on our front page

Sayed's Second Quarter Meeting

Anonymous

Guest
Sayed is having his second quarter overview for the US business July 30. The last when he was quite evasive on any questions asked and just praised Dan Barton on the MAS division despite it be 5% off revenue goals.

Nobody will ask any questions about the debunked move, because no straight answers will be given. Will he suck up to Barton again despite another poor quarter for the MAS group and people are flocking out of that division?

Should be another waste of time.
 












Don't put it past anyone that could happen. They cant make up their mind where to move people to because of all the poor management, poor planning, so anything is possible. There have been rumors in the past that IMS is for sale because the investors, just like SDI's prior investors are tired of all their bullshit and mismanagement and want out..

All these upper crust idiots want is to fatten their paychecks and live like kings.....